Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Vitamin D/Calcium Report Draws Industry Fire

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Preventive Service Task Force releases a meta-analysis looking at whether available research supports an association between the use of vitamin D and calcium and fracture prevention. Trials of vitamin D use alone or with calcium showed no statistically significant reduction in fractures among subjects in the control groups, the panel found.

You may also be interested in...



Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis

New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.

Nutrition Scientists Float “Least-Harm Strategy” To Allow Health Claims

Presenters at the IFT Wellness conference recommend that nutrition science move beyond randomized controlled trials – which typically are ill-suited to assess nutrient benefits – so development of new food and supplement products is not impeded.

IoM Sets Vitamin D Intake Levels Below Experts' Expectations

The Institute of Medicine sets its daily vitamin D daily allowance well below the amounts some nutrition experts suggest.

Topics

UsernamePublicRestriction

Register

PS106266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel